Poisons Board warns against misuse of Ozempic for weight loss
Health & Science
By
Ronald Kipruto
| Aug 19, 2025
Pharmacy and Poisons Board CEO Fred Siyoi. [File, Standard]
The Pharmacy and Poisons Board (PPB) has cautioned the public against using semaglutide, commonly sold as Ozempic, for weight loss.
In a statement on Tuesday, August 19, Chief Executive Officer Fred Siyoi said the drug is a prescription-only medicine approved for treating type 2 diabetes, but its misuse for cosmetic purposes is rising.
“The Board wishes to bring to the attention of the public that semaglutide is a Prescription-Only Medicine, and its unsupervised or off-label use may result in serious health outcomes,” said Siyoi.
The Board, mandated to regulate the quality, safety, and distribution of drugs, health products, and technologies in Kenya, also highlighted possible side effects.
READ MORE
Parliament to have say on sale of State corporations
Family Bank half-year profit up 39pc to Sh2.3b
Stays of application of EAC tariffs raises concerns amidst new rates
Three business lessons from Harambee Stars CHAN exploits
Is there a limit to hustling even as it is celebrated in Kenya?
Experts caution: Kenya's VASP Bill holds the future of Web3
Bringing Nairobi's infrastructure up to speed with its rising stature
Markets cautious after Zelensky-Trump talks
They include low blood sugar (hypoglycemia), eye conditions, acid reflux, and intestinal obstruction, which can range from mild to severe.
“While the benefits of Semagluude outweigh its risks, serious safety concerns continue to be raised,” he added.
The Pharmacy Board has urged the public to avoid misuse of the drug and to report any suspected side effects or poor-quality products.
The warning follows a growing trend in the country, including by social media influencers and marketing firms, that are now promoting semaglutide as a shortcut to weight loss, without informing the masses of the side effects.